Skip to main content

Market Overview

Nanobiotix, LianBio Ink NBTXR3 Development Pact In Asia For Solid Tumor Settings

Share:
Nanobiotix, LianBio Ink NBTXR3 Development Pact In Asia For Solid Tumor Settings
  • Nanobiotix (NASDAQ: NBTXhas announced a partnership with LianBio to develop and commercialize Nanobiotix's lead product candidate NBTXR3, in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore, and Thailand.
  • NBTXR3 comprises functionalized hafnium oxide nanoparticles that are administered via one-time intratumoral injection and activated by radiotherapy.
  • The product candidate is being evaluated primarily in locally advanced head and neck squamous cell carcinoma.
  • Under the terms of the agreement, Nanobiotix will receive a $20 million upfront payment and is entitled to receive up to an aggregate of $220 million in potential milestone payments.
  • Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories.
  • LianBio will participate in the Nanobiotix global Phase 3 registrational study evaluating NBTXR3 in head and neck cancer by enrolling 100 patients in China in the study.
  • LianBio will fund all development and commercialization expenses in the collaboration territory, and Nanobiotix will continue to fund all development and commercialization expenses in all other geographies.
  • Price Action: NBTX shares closed at $15.5 on Tuesday.
 

Related Articles (NBTX)

View Comments and Join the Discussion!

Posted-In: Briefs Solid TumorBiotech News Health Care Contracts Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com